TY - JOUR
T1 - Updated Management of Colorectal Cancer Liver Metastases
T2 - Scientific Advances Driving Modern Therapeutic Innovations
AU - Patel, Ranish K.
AU - Rahman, Shahrose
AU - Schwantes, Issac R.
AU - Bartlett, Alexandra
AU - Eil, Robert
AU - Farsad, Khashayar
AU - Fowler, Kathryn
AU - Goodyear, Shaun M.
AU - Hansen, Lissi
AU - Kardosh, Adel
AU - Nabavizadeh, Nima
AU - Rocha, Flavio G.
AU - Tsikitis, V. Liana
AU - Wong, Melissa H.
AU - Mayo, Skye C.
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/1
Y1 - 2023/1
N2 - Colorectal cancer is the second leading cause of cancer-related deaths in the United States and accounts for an estimated 1 million deaths annually worldwide. The liver is the most common site of metastatic spread from colorectal cancer, significantly driving both morbidity and mortality. Although remarkable advances have been made in recent years in the management for patients with colorectal cancer liver metastases, significant challenges remain in early detection, prevention of progression and recurrence, and in the development of more effective therapeutics. In 2017, our group held a multidisciplinary state-of-the-science symposium to discuss the rapidly evolving clinical and scientific advances in the field of colorectal liver metastases, including novel early detection and prognostic liquid biomarkers, identification of high-risk cohorts, advances in tumor-immune therapy, and different regional and systemic therapeutic strategies. Since that time, there have been scientific discoveries translating into therapeutic innovations addressing the current management challenges. These innovations are currently reshaping the treatment paradigms and spurring further scientific discovery. Herein, we present an updated discussion of both the scientific and clinical advances and future directions in the management of colorectal liver metastases, including adoptive T-cell therapies, novel blood-based biomarkers, and the role of the tumor microbiome. In addition, we provide a comprehensive overview detailing the role of modern multidisciplinary clinical approaches used in the management of patients with colorectal liver metastases, including considerations toward specific molecular tumor profiles identified on next generation sequencing, as well as quality of life implications for these innovative treatments.
AB - Colorectal cancer is the second leading cause of cancer-related deaths in the United States and accounts for an estimated 1 million deaths annually worldwide. The liver is the most common site of metastatic spread from colorectal cancer, significantly driving both morbidity and mortality. Although remarkable advances have been made in recent years in the management for patients with colorectal cancer liver metastases, significant challenges remain in early detection, prevention of progression and recurrence, and in the development of more effective therapeutics. In 2017, our group held a multidisciplinary state-of-the-science symposium to discuss the rapidly evolving clinical and scientific advances in the field of colorectal liver metastases, including novel early detection and prognostic liquid biomarkers, identification of high-risk cohorts, advances in tumor-immune therapy, and different regional and systemic therapeutic strategies. Since that time, there have been scientific discoveries translating into therapeutic innovations addressing the current management challenges. These innovations are currently reshaping the treatment paradigms and spurring further scientific discovery. Herein, we present an updated discussion of both the scientific and clinical advances and future directions in the management of colorectal liver metastases, including adoptive T-cell therapies, novel blood-based biomarkers, and the role of the tumor microbiome. In addition, we provide a comprehensive overview detailing the role of modern multidisciplinary clinical approaches used in the management of patients with colorectal liver metastases, including considerations toward specific molecular tumor profiles identified on next generation sequencing, as well as quality of life implications for these innovative treatments.
KW - Adoptive T-Cell Therapy
KW - Circulating Hybrid Cells
KW - Colorectal Liver Metastases
KW - Hepatic Arterial Infusion
KW - Molecular Profiling
KW - Quality of Life
KW - Surgical Resection
KW - Tumor Microbiome
UR - http://www.scopus.com/inward/record.url?scp=85174357010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174357010&partnerID=8YFLogxK
U2 - 10.1016/j.jcmgh.2023.08.012
DO - 10.1016/j.jcmgh.2023.08.012
M3 - Review article
C2 - 37678799
AN - SCOPUS:85174357010
SN - 2352-345X
VL - 16
SP - 881
EP - 894
JO - CMGH
JF - CMGH
IS - 6
ER -